Analyst Price Targets — IQV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 12:37 pm | — | Mizuho Securities | $215.00 | $165.62 | TheFly | Iqvia price target lowered to $215 from $266 at Mizuho |
| February 19, 2026 1:34 pm | — | Truist Financial | $245.00 | $165.64 | TheFly | Iqvia price target lowered to $245 from $290 at Truist |
| February 11, 2026 2:09 pm | — | Morgan Stanley | $240.00 | $178.88 | TheFly | Iqvia price target lowered to $240 from $265 at Morgan Stanley |
| February 6, 2026 1:26 pm | — | UBS | $240.00 | $184.01 | TheFly | Iqvia price target lowered to $240 from $280 at UBS |
| February 6, 2026 1:20 pm | — | BMO Capital | $250.00 | $184.75 | TheFly | Iqvia price target lowered to $250 from $260 at BMO Capital |
| February 6, 2026 12:33 pm | — | Stifel Nicolaus | $220.00 | $184.67 | TheFly | Iqvia price target lowered to $220 from $273 at Stifel |
| February 6, 2026 10:34 am | Luke Sergott | Barclays | $210.00 | $180.96 | TheFly | Iqvia price target lowered to $210 from $230 at Barclays |
| February 5, 2026 9:01 pm | Elizabeth Anderson | Evercore ISI | $225.00 | $180.96 | StreetInsider | IQVIA Holdings (IQV) PT Lowered to $225 at Evercore ISI |
| January 9, 2026 12:09 pm | — | Mizuho Securities | $266.00 | $243.19 | TheFly | Iqvia price target raised to $266 from $250 at Mizuho |
| January 8, 2026 1:33 pm | Dan Leonard | UBS | $280.00 | $242.66 | TheFly | Iqvia price target raised to $280 from $250 at UBS |
Latest News for IQV
Elo Mutual Pension Insurance Co lifted its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 97.1% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,160 shares of the medical research company's stock after purchasing an additional 14,362 shares during the quarter. Elo
DNB Asset Management AS trimmed its position in shares of IQVIA Holdings Inc. (NYSE: IQV) by 9.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 81,265 shares of the medical research company's stock after selling 8,000 shares during the quarter. DNB
IQVIA Holdings delivered strong Q4 and full-year 2025 results, confirming its leadership in data, analytics, and clinical execution. Despite macro headwinds and cautious biotech spending, IQV maintained robust profitability, near-100% cash conversion, and expanded its $32.7B backlog. EPS guidance for 2026 was below consensus, triggering a selloff, but I remain bullish due to durable bookings, backlog, and elite…
Artisan Partners Limited Partnership grew its stake in IQVIA Holdings Inc. (NYSE: IQV) by 4.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,433,957 shares of the medical research company's stock after buying an additional 161,085
IQVIA Holdings Inc. (IQV) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.